Core Insights - The stock of innovative drug company Yaojie Ankang-B experienced significant volatility, initially rising by 63.73% before closing down 53.73% on September 16, with an intraday fluctuation exceeding 110% [1] - The innovative drug sector has been a focal point for investors this year, with Yaojie Ankang-B being included in certain innovative drug indices, impacting the net asset values of related index-tracking funds [1] - The surge in trading volume for Yaojie Ankang-B, from a daily turnover of around 30 million yuan to over 2.5 billion yuan in the days following its index inclusion, has raised concerns about potential arbitrage activities [1] Industry Overview - The Tianhong Innovative Drug ETF (517380) focuses on the entire innovative drug industry chain, which includes preclinical research, clinical research, custom manufacturing, and commercialization, aiming to reduce investment uncertainties and enhance long-term returns [2] - As of September 16, the Tianhong Innovative Drug ETF has recorded a year-to-date increase of 67.69%, outperforming other industry ETFs by approximately 10 percentage points [2] - Analysts predict that 2025 will mark a significant growth year for China's innovative drug industry, driven by high-value business development transactions, profitability improvements among leading companies, and an increasingly favorable policy environment [2] - The Chinese innovative drug market is projected to exceed 2 trillion yuan by 2030, with a compound annual growth rate of 24.1% [2]
不含药捷安康-B！创新药ETF天弘（517380）跟踪指数今年以来涨超67%，位居全市场行业类ETF跟踪指数涨幅第一